MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31

MANNKIND CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$3.09+0.05 (+1.64%)

Close on Oct 19, 2026

Market cap: $955.40M
P/E (TTM): –
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$348.97MFY2025, +88.2% a year since FY2011

Where these numbers come from

Parsed from the XBRL in Mannkind's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Mar 3, 2017
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MNKD.

Revenue growth30.5% · median 30.9%

Gross margin89.8% · median 54.0%

Operating margin2.3% · median 32.6%

Net margin-11.1% · median 30.7%

Company	Revenue	Growth
ANIP	$978.38M	+30.9%
AMPH	$730.02M	+1.0%
LQDA	$450.91M	+2233.6%
MNKD	$393.63M	+30.5%
IRWD	$389.32M	+26.2%
LGND	$290.54M	+54.9%

Company

Next earnings (est.): Nov 4, 2026, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 241
Held by institutions: 56.7%
Auditor: Deloitte & Touche LLP
SEC CIK: 899460

Advertisement
300 × 250